Last reviewed · How we verify
NCT04617873
DBS and SCS Therapy Improve Motor Function in Multiple System Atrophy With Predominant Parkinsonism
NA trial testing Bilateral STN-DBS and T10-T12 SCS in Multiple System Atrophy, Parkinson Variant (Disorder) in 20 participants. Status unknown.
1 January 2023
Quick facts
| Lead sponsor | zhangyuqing |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 5 January 2021 |
| Primary completion | 1 January 2023 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bilateral STN-DBS and T10-T12 SCS
Conditions studied
- Multiple System Atrophy, Parkinson Variant (Disorder) — all drugs for Multiple System Atrophy, Parkinson Variant (Disorder) →
Sponsor
zhangyuqing
Who can join
Adults 30 to 75, any sex, with Multiple System Atrophy, Parkinson Variant (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multiple system atrophy (MSA) is a debilitating and fatal neurodegenerative disorder and symptomatic therapeutic strategies are still limited.The parkinsonian type of MSA (MSA-P) has parkinsonian symptoms as its prominent manifestation, although Deep brain stimulation (DBS) at the subthalamic nucleus or globus pallidus interna has been an established treatment for Parkinson's disease patients, it is mostly ineffective in MSA-P patients, the improvement in motor function as short-lasting and rapidly followed by the early appearance of freezing of gait (FOG) and postural instability that counteracted DBS benefits and often leads to significant disability and loss of quality of life. Recently, some pilot studies demonstrated the safety and significant therapeutic outcome of SCS for FOG.The purpose of this clinical study is to understand the effectiveness of DBS combined with SCS for symptomatic treatment of MSA-P.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04617873
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04617873 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by zhangyuqing
- Last refreshed: 14 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04617873.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing